Literature DB >> 3020531

The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.

G Zsilla, P Földi, G Held, A M Székely, J Knoll.   

Abstract

The action of clorgyline and (-)deprenyl on the dynamics of dopaminergic and serotonergic transmission in the rat brain was compared. It was found, that daily administration of 0.25 mg/kg sc clorgyline, a specific MAO A inhibitor, reduced the turnover rate of both dopamine and serotonin after two weeks of injections. The treatment for two or four weeks with 0.25 mg/kg sc (-)deprenyl, a specific MAO B inhibitor, enhanced the turnover rate of dopamine and the fractional rate constant of dopamine efflux, reflecting an increased utilization rate of this amine in the striatum. Beside the augmentation of the dopamine turnover rate, the dopaminergic tone was also elevated by the reduction of the dopamine uptake in the striatum. Two week injections with the same dose of (-)deprenyl did not change the dynamics of serotonergic transmission.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020531

Source DB:  PubMed          Journal:  Pol J Pharmacol Pharm        ISSN: 0301-0244


  9 in total

1.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

2.  Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition.

Authors:  H K Wayment; J O Schenk; B A Sorg
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

3.  New mechanisms of action of irreversible monoamine oxidase type B inhibitors.

Authors:  X M Li; A V Juorio; I A Paterson; A A Boulton
Journal:  J Psychiatry Neurosci       Date:  1993-07       Impact factor: 6.186

4.  Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo.

Authors:  I Lamensdorf; S Porat; R Simantov; J P Finberg
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

5.  Voltammetric detection of the release of 5-hydroxyindole compounds throughout the sleep-waking cycle of the rat.

Authors:  R Cespuglio; N Sarda; A Gharib; N Chastrette; F Houdouin; C Rampin; M Jouvet
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

6.  The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions.

Authors:  E Scarr; D M Wingerchuk; A V Juorio; I A Paterson
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

Review 7.  The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog.

Authors:  N W Milgram; G O Ivy; E Head; M P Murphy; P H Wu; W W Ruehl; P H Yu; D A Durden; B A Davis; I A Paterson
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

8.  Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl.

Authors:  C P de la Cruz; E Revilla; V Steffen; J A Rodríguez-Gómez; J Cano; A Machado
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

9.  Accumulation of 123I-Ioflupane Is a Useful Marker of the Efficacy of Selegiline Monotherapy in Drug-Naïve Parkinson's Disease.

Authors:  Hidetomo Murakami; Tetsuhito Nohara; Masanobu Uchiyama; Yoshiyuki Owan; Akinori Futamura; Azusa Shiromaru; Setsuro Tsukada; Yu Saito; Takeshi Kuroda; Satoshi Yano; Seiichiro Ishigaki; Hirotaka Katoh; Jiro Munechika; Yoshimitsu Ohgiya; Takehiko Gokan; Kenjiro Ono
Journal:  Front Aging Neurosci       Date:  2017-09-29       Impact factor: 5.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.